HN1999000029A - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
HN1999000029A
HN1999000029A HN1999000029A HN1999000029A HN1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A
Authority
HN
Honduras
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
HN1999000029A
Other languages
English (en)
Spanish (es)
Inventor
Warner Lambert Company
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN1999000029A publication Critical patent/HN1999000029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HN1999000029A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. HN1999000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
HN1999000029A true HN1999000029A (es) 1999-09-29

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000029A HN1999000029A (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (https=)
JP (1) JP2002506818A (https=)
KR (1) KR20010041916A (https=)
AR (1) AR018113A1 (https=)
AU (1) AU1591699A (https=)
BR (1) BR9815745A (https=)
CA (1) CA2309588A1 (https=)
CO (1) CO5070670A1 (https=)
GT (1) GT199900039A (https=)
HN (1) HN1999000029A (https=)
MY (1) MY140504A (https=)
NZ (1) NZ505994A (https=)
PA (1) PA8469001A1 (https=)
PE (1) PE20000348A1 (https=)
SV (1) SV1999000026A (https=)
UY (1) UY25436A1 (https=)
WO (1) WO1999047138A1 (https=)
ZA (1) ZA992106B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
CN1077885C (zh) * 1996-05-17 2002-01-16 沃尼尔·朗伯公司 联苯基磺酰胺基质金属蛋白酶抑制剂
KR20000057444A (ko) * 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
AU1591699A (en) 1999-10-11
NZ505994A (en) 2003-10-31
ZA992106B (en) 1999-09-30
EP1063991A1 (en) 2001-01-03
GT199900039A (es) 2000-09-06
AR018113A1 (es) 2001-10-31
BR9815745A (pt) 2000-11-14
KR20010041916A (ko) 2001-05-25
WO1999047138A1 (en) 1999-09-23
MY140504A (en) 2009-12-31
JP2002506818A (ja) 2002-03-05
CO5070670A1 (es) 2001-08-28
PE20000348A1 (es) 2000-05-22
PA8469001A1 (es) 2002-09-17
CA2309588A1 (en) 1999-09-23
SV1999000026A (es) 2000-01-18
UY25436A1 (es) 2001-10-25

Similar Documents

Publication Publication Date Title
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
ES2178298T3 (es) Compuestos anti-inflamatorios.
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
ES2188285T3 (es) Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares.
GT199800134A (es) Terapia de combinacion.
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
UY25268A1 (es) Inhibicion de la oxidacion de lipoproteinas
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
UY25299A1 (es) Combinaciones de estatina-eter carboxialquílico
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PA8452701A1 (es) Agonistas de prostaglandinas
PT1140181E (pt) Terapia de combinacao de radiacao e um inibidor de cox-2 para o tratamento da neoplasia
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
HN1999000029A (es) Combinaciones de estatina-inhibidor de mmp.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
MXPA97001884A (es) Composiciones para el tratamiento de trastornos enla piel.
ECSP088117A (es) Agente desinfectante
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
ATE333279T1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
TR200100901T2 (tr) Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi
DE60021350D1 (de) Mmp-hemmer bei bindegewebserweichung
GT199900037A (es) Nuevas composiciones herbicidas.
FR2785808B1 (fr) Association riluzole et alpha-tocopherol